Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Lau, George
Sangro, Bruno
Crysler, Oxana V.
Sukeepaisarnjaroen, Wattana
Lipatov, Oleg
Morimoto, Manabu
Archambeaud, Isabelle
Burgio, Valentina
Phuong, Le Thi Tuyet
Chao, Yee
Peron, Jean-Marie
Berres, Marie-Luise
Ko, Yoo-Joung
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
机构：
[1] Human & Hlth Med Grp, Human & Hlth Clin Trial Ctr, Hong Kong, Peoples R China
[2] Clinica Univ Navarra, CIBEREHD, Liver Unit & HPB Oncol Area, Pamplona, Spain
[3] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[4] Khon Kaen Univ, Srinagarind Hosp, Dept Med, Khon Kaen, Thailand
[5] Bashkir State Med Univ, Ufa, Russia
[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[7] Nantes Univ, CHU Nantes, Inst Malad Appareil Digestif IMAD, Hepato Gastro Enterol & Assista Nutr, Nantes, France
[8] Ist Sci San Raffaele, Dept Med Oncol, Milan, Italy
[9] Peoples Hosp 115, Ho Chi Minh City, Vietnam
[10] Vet Gen Hosp, Dept Oncol, Taipei, Taiwan
[11] Gastro Enterol Hepatol, Ho pital Purpan, Toulouse, France
[12] Univ Hosp RWTH Aachen, Clin Gastroenterol Metab Dis & Internal Med Inten, Aachen, Germany
[13] Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Aachen, Germany
[14] Unity Hlth Toronto, St Michaels Hosp, Toronto, ON, Canada
[15] AstraZeneca, Gaithersburg, MD USA
[16] AstraZeneca, Wilmington, DE USA
[17] Cornell Univ, Dept Med, Weill Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4073
引用
收藏
页数：1
相关论文
共 47 条
  • [1] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Lau, George
    Cheng, Ann-Lii
    Sangro, Bruno
    Kudo, Masatoshi
    Kelley, Robin Kate
    Tak, Won Young
    Gasbarrini, Antonio
    Reig, Maria
    Lim, Ho Yeong
    Tougeron, David
    De Toni, Enrico N.
    Tam, Vincent C.
    Mody, Kabir
    Gong, Jun
    Mccoy, Carrie L.
    Gupta, Charu
    Makowsky, Mallory
    Negro, Alejandra
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, L. S.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
  • [3] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [4] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [5] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
  • [6] Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab ( T) plus Durvalumab (D) in Patients with Unresectable Hepatocellular Carcinoma (uHCC) in the Phase 3 HIMALAYA Trial
    De Toni, E. M.
    Sangro, B.
    Chan, S. L.
    Kudo, M.
    Kelley, R. K.
    -K, Kang Y.
    Rimassa, L.
    Varela, M.
    Dayyani, F.
    Makowsky, M.
    Marcovitz, M.
    Mccoy, C. L.
    Negro, A.
    Abou-Alfa, G.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 240
  • [7] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Rimassa, L.
    Dayyani, F.
    Kelley, R. K.
    Sangro, B.
    Chan, S. L.
    Mccoy, C. L.
    Paskow, M. J.
    Makowsky, M.
    Gupta, C.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
  • [8] Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)
    Galle, P. R.
    Crysler, O., V
    Yarchoan, M.
    Furuse, J.
    Sukeepaisarnjaroen, W.
    Thinh, N. T.
    Masi, G.
    Lim, H. Y.
    Varela, M.
    Gupta, C.
    Makowsky, M.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 129 - 129
  • [9] Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Monzon, M. E. Reig
    Tam, V. C.
    Sangro, B.
    Archambeaud, I.
    Kelley, R. K.
    Chan, S. L.
    Kudo, M.
    Masi, G.
    Paskow, M. J.
    Makowsky, M.
    Gupta, C.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S75 - S76
  • [10] Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
    Crysler, Oxana V.
    Yarchoan, Mark
    Furuse, Junji
    Galle, Peter R.
    Sukeepaisarnjaroen, Wattana
    Nguyen Tien Thinh
    Masi, Gianluca
    Lim, Ho Yeong
    Varela, Maria
    Gupta, Charu
    Makowsky, Mallory
    Negro, Alejandra
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 551 - 551
12345